← Leaderboards
Theodore B Moore
University Of California Los Angeles
$12,385
Attributed
$12,385
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.9K · FY2005–06$5K$3.8K$2.5K$1.3K$0
'05
'06
Funding mix
By agency
NIH$12,385 · 3
By mechanism
M01$12,385 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Connie L Kasari$33,208,285
- James T. McCracken$25,405,162
- Elizabeth R Sowell$36,362,090
- Yvonne J Bryson$45,728,199
- Kevin A. Pelphrey$38,637,732
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectBlood Disorder ChemotherapyBody CompositionChildrenClinical Trial Phase IClinical Trial Phase IiDoxorubicinDrug Screening /EvaluationHuman Therapy EvaluationHypogammaglobulinemiaIntravenous AdministrationMonoclonal AntibodyPatient Oriented ResearchPediatric PharmacologyPharmacokineticsAntineoplastic AntibioticsThrombocytopenic PurpuraAntineoplastics
Grant awards (5)
PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED DENDRITIC CEL$1,201
M01 · FY2006 · RR · contact PI
OPEN LABEL, PHASE I/II TRIAL OF RITUXIMAB FOR CHRONIC, SEVERE IDIOPATHIC THRO$4,620
M01 · FY2005 · RR
IMPACT OF BODY COMPOSITION ON PHARMACOKINETICS OF DOXORUBICIN IN PEDIATRIC PA$288
M01 · FY2005 · RR
Impact of Body Composition on Pharmacokinetics of Doxorubicin in Pediatric Pa...$3,274
M01 · FY2004 · RR
Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thro...$3,002
M01 · FY2004 · RR